Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Nader Rifai, Ph.D.

Co-Author

This page shows the publications co-authored by Nader Rifai and Julie Buring.
Connection Strength

1.114
  1. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005 Jul 20; 294(3):326-33.
    View in: PubMed
    Score: 0.080
  2. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003 Jan 28; 107(3):391-7.
    View in: PubMed
    Score: 0.068
  3. Is C-reactive protein specific for vascular disease in women? Ann Intern Med. 2002 Apr 02; 136(7):529-33.
    View in: PubMed
    Score: 0.064
  4. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001 Jan 30; 103(4):491-5.
    View in: PubMed
    Score: 0.059
  5. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23; 342(12):836-43.
    View in: PubMed
    Score: 0.056
  6. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Res. 2016 12 15; 76(24):7160-7167.
    View in: PubMed
    Score: 0.044
  7. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):855-61.
    View in: PubMed
    Score: 0.034
  8. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2013 Jan 16; 105(2):95-103.
    View in: PubMed
    Score: 0.034
  9. Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012 Dec 13; 120(25):4929-37.
    View in: PubMed
    Score: 0.033
  10. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21(1):82-91.
    View in: PubMed
    Score: 0.031
  11. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010 Aug; 56(8):1252-60.
    View in: PubMed
    Score: 0.028
  12. Association of resistin promoter polymorphisms with plasma resistin levels and type 2 diabetes in women and men. Int J Mol Epidemiol Genet. 2010; 1(3):167-74.
    View in: PubMed
    Score: 0.028
  13. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009 Sep 17; 361(12):1152-63.
    View in: PubMed
    Score: 0.027
  14. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009 May; 55(5):888-94.
    View in: PubMed
    Score: 0.026
  15. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009 Feb 24; 119(7):931-9.
    View in: PubMed
    Score: 0.026
  16. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care. 2009 Feb; 32(2):329-34.
    View in: PubMed
    Score: 0.025
  17. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008 Sep 02; 118(10):993-1001.
    View in: PubMed
    Score: 0.025
  18. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol. 2008 Jul 08; 52(2):124-31.
    View in: PubMed
    Score: 0.025
  19. Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis. 2009 Jan; 202(1):282-8.
    View in: PubMed
    Score: 0.024
  20. Plasma concentration of heat shock protein 27 and risk of cardiovascular disease: a prospective, nested case-control study. Clin Chem. 2008 Jan; 54(1):139-46.
    View in: PubMed
    Score: 0.024
  21. Intercellular adhesion molecule 1 (ICAM1) Lys56Met and Gly241Arg gene variants, plasma-soluble ICAM1 concentrations, and risk of incident cardiovascular events in 23,014 initially healthy white women. Stroke. 2007 Dec; 38(12):3152-7.
    View in: PubMed
    Score: 0.023
  22. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia. 2007 Oct; 50(10):2076-84.
    View in: PubMed
    Score: 0.023
  23. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med. 2007 Aug; 120(8):720-7.
    View in: PubMed
    Score: 0.023
  24. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18; 298(3):309-16.
    View in: PubMed
    Score: 0.023
  25. Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem. 2007 May; 53(5):845-51.
    View in: PubMed
    Score: 0.022
  26. High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch Ophthalmol. 2007 Mar; 125(3):300-5.
    View in: PubMed
    Score: 0.022
  27. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007 Feb 14; 297(6):611-9.
    View in: PubMed
    Score: 0.022
  28. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006 Sep 20; 296(11):1363-70.
    View in: PubMed
    Score: 0.022
  29. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation. 2006 Aug 01; 114(5):381-7.
    View in: PubMed
    Score: 0.022
  30. A prospective study of hemoglobin A1c concentrations and risk of breast cancer in women. Cancer Res. 2006 Mar 01; 66(5):2869-75.
    View in: PubMed
    Score: 0.021
  31. C-reactive protein and the risk of developing hypertension. JAMA. 2003 Dec 10; 290(22):2945-51.
    View in: PubMed
    Score: 0.018
  32. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003 Dec 16; 108(24):2993-9.
    View in: PubMed
    Score: 0.018
  33. Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women. Am J Med. 2003 Apr 15; 114(6):438-44.
    View in: PubMed
    Score: 0.017
  34. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14; 347(20):1557-65.
    View in: PubMed
    Score: 0.017
  35. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002 Oct 01; 22(10):1668-73.
    View in: PubMed
    Score: 0.017
  36. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol. 2002 May 01; 89(9):1117-9.
    View in: PubMed
    Score: 0.016
  37. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001 Jul 18; 286(3):327-34.
    View in: PubMed
    Score: 0.015
  38. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999 Aug 17; 100(7):713-6.
    View in: PubMed
    Score: 0.013
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.